Case-Based Roundtable Meetings Spotlight July 1 2021 | Case-Based Roundtable Meetings Spotlight

Roundtable Discussion: Factors for Choosing an AR-Targeted Therapy Considered for Prostate Cancer

August 02, 2021

Clinical Articles

Alan H. Bryce, MD, the chair of the Genitourinary Disease Group at the Mayo Clinic leads a Targeted Oncology Rountable Discussion on factors for choosing AR-targeted therapy for prostate cancer. He is joined by Robert Yoo, DO, Justin Goldfarb, DO, Miguel Gonzalez Velez, MD, Gehan Botrus, MD, Fei Gu, MD, Rajinder Grover, MD.

Roundtable Discussion: Ailawadhi Debates Whether MRD Currently Affects Treatment Decisions in Multiple Myeloma

August 02, 2021

In a rountable Targeted Oncology talk, Sikander Ailawadhi, MD, leads a discussion on whether MRD affects multiple myeloma treatment decisions. He is joined by Ricardo Parrondo, MD Jeffrey Bubis, DO, Mathew Luke, MD, Sushma Simha Nakka, MD, and Thomas Cartwright, MD.

Triplet Regimen Options Reviewed for Multiple Myeloma

July 28, 2021

Clinical Articles

Two years after being diagnosed with stage II multiple myeloma, a patient continuing on daratumumab plus lenalidomide maintenance showed concerning symptoms during routine follow-up, explained Ruben Niesvizky, MD.

Roundtable Discussion: The Role for Selinexor Explored in Multiple Myeloma

July 27, 2021

Clinical Articles

The treatment plan for a woman with multiple myeloma, including which imaging to order, choice of second-line therapy, managing comorbidities, and backbone therapy choice, was discussed during a recent Cased-Base Roundtable event led by Clifton C. Mo, MD.

Roundtable Discussion: Lunning Compares the Benefits and Disadvantages of Using Tafasitamab-Lenalidomide in R/R DLBCL

July 27, 2021

Clinical Articles

Matthew A. Lunning, DO began a Case-Based Roundtable event by asking a group of oncologists how diffuse large b-cell lymphoma in handling in their practices. The responses varied, considering some of the oncologists worked in academic centers and some worked in the community setting.

Roundtable Discussion: Gadgeel Leads a Discussion on the Timing for RET-Targeted Therapy in NSCLC

July 25, 2021

Clinical Articles

According to a poll, the majority of physicians would wait for molecular testing on a patient metastatic lung adenocarcinoma. Then, upon diagnosis of RET-mutant non–small cell lung cancer, a group of oncologists explained how they would go about treatment for the patient.

Venugopal Considers BTK and BCL2 Inhibitors in Patient With CLL

July 22, 2021

Clinical Articles

Treatment for a patient with chronic lymphocytic leukemia who has comorbidities including hypertension and atrial fibrillation was the topic of discussion during a Targeted Oncology Case-Based Roundtable event led by Parameswaran Venugopal, MD.

Tafasitamab/Lenalidomide Combo Demonstrates Favorable Efficacy in DLBCL

July 21, 2021

Clinical Articles

In the case that a clinical trial is not an option for a 75-year-old male patient with diffuse large B-cell lymphoma who is ineligible for transplant due to older age and high risk. Herbert A. Eradat, MD, explains his treatment plan.

Nadeem Considers Transplant and Quadruplet Regimens in Newly Diagnosed Multiple Myeloma

July 20, 2021

Clinical Articles

In an interview with Targeted Oncology, Omar Nadeem, MD, the clinical director of the Myeloma Cellular Therapies Program at the Harvard Medical School and physician at the Dana-Farber Cancer Institute, discusses transplant and quadruplet regimens in newly diagnosed multiple myeloma.